The aim of this study was to assess the frequency of potential drug-drug interactions (pDDIs) and adverse drug events (ADEs) associated with antimycotics in hospitalized patients with hematopoietic SCT (HSCT). Of the 120 HSCT recipients evaluated, 36 received antimycotics. A total of 124 ADEs were recorded in 32 of the 36 patients treated, with 54 ADEs being possibly and 9 probably related to antimycotics. Of the treatments with amphotericin B, 93% were associated with one or more possible and 36% with probable ADEs. The corresponding figures for lipid-based amphotericin B were 100% and 7%, for voriconazole 68% and 11% and for caspofungin 70% and 0%. A total of 57 potentially severe DDIs associated with antimycotics were detected in 31 of the 36 patients. Of these, 14 DDIs were a possible cause of an ADE and 5 (4 times a combination of voriconazole with CYA and once a combination of CYA with conventional amphotericin B) were probably related. Although the prevalence of pDDIs and ADEs is high in HSCT patients, ADEs related with a high probability to treatment with antimycotics are rare. Regarding the high prevalence of pDDIs, our findings underscore the importance of close monitoring of laboratory and clinical parameters, as well as dose adjustment for critical drugs, in patients with HSCT.
Introduction
Invasive aspergillosis occurs in 2-26% of patients undergoing hematopoietic SCT (HSCT). The frequency is higher in allogeneic than in autologous transplant recipients. 1 Other important risk factors for invasive aspergillosis are protracted neutropenia and immunosuppressive treatment of GVHD. Mortality from invasive aspergillosis is high, ranging between 66.6 and 80% in HSCT patients. 1 Antimycotic drugs for first-line treatment of invasive aspergillosis are amphotericin B and voriconazole, whereas caspofungin and itraconazole are considered as second-line treatment options. 2, 3 Amphotericin B deoxycholate (conventional amphotericin B) has long been considered as the gold standard, 2, 3 but its use is limited by nephrotoxicity. Lipid formulations (liposomal amphotericin B or amphotericin B lipid complex) are less nephrotoxic than conventional amphotericin B while retaining the drug's activity. 4, 5 Clinical evidence for the combination of antimycotic drugs is limited and its use is experimental. 6, 7 As HSCT recipients are often treated with multiple drugs, they are at risk for drug-drug interactions (DDIs) and adverse drug events (ADEs). 8 Of the antimycotic drugs used for the treatment of invasive aspergillosis, voriconazole poses a high risk for pharmacokinetic DDIs, as it is a known substrate and inhibitor of several cytochrome P450 isozymes (CYP), for example, CYP 2C19, 2C9 and 3A4. [9] [10] [11] Nivoix et al. 10 considered voriconazole as a moderately strong CYP inhibitor, showing a two to fivefold increase in area under the curve values of sensitive CYP 3A4 substrates. Immunosuppressants such as CYA, sirolimus and tacrolimus are commonly used in HSCT recipients and are known substrates of CYP 3A4. Owing to their narrow therapeutic range, a combination with voriconazole requires special attention. Otherwise, voriconazole is generally well tolerated. The most frequently observed ADEs include liver enzyme abnormalities, visual adverse effects, central nervous system disorders (for example, hallucinations), electrolyte disturbances and skin reactions. 3, 12, 13 The most important ADEs limiting treatment with amphotericin B are nephrotoxicity, electrolyte disturbances such as hypokalemia and/or hypomagnesemia, and infusion-related reactions such as chills and fever. 13, 14 DDIs with amphotericin B are primarily limited to compounds that also impair renal function (for example, CYA, aminoglycosides) and/or electrolyte balance. 13 Pharmacokinetic DDIs are not expected, as amphotericin B is not a substrate, inducer or inhibitor of CYP 450 isozymes. 13 Caspofungin belongs to a newer class of antimycotics, the echinocandins. The risk of pharmacokinetic DDIs is low, as caspofungin is only minimally metabolized by CYPs, and has not been shown to affect the metabolism of CYP substrates. 13, 15 The combination of caspofungin with CYA is not recommended, as CYA increases the area under the curve value of caspofungin by 35% and elevations of transaminase levels have also been reported. 16 Retrospective analyses of patient data, however, did not show a significant risk for clinically relevant hepatotoxicity. [17] [18] [19] Clinically relevant ADEs of caspofungin include symptoms associated with histamine release, elevated liver enzymes and hypokalemia. 12, 13, 16 Surprisingly, few data exist with regard to the safety of drugs for the treatment of invasive aspergillosis in HSCT patients. The aim of this retrospective study was, therefore, to assess the frequency of potential DDIs (pDDIs) and of ADEs associated with amphotericin B, voriconazole and/or caspofungin in HSCT recipients.
Methods

Study population and data collection
Of the 156 patients consecutively admitted for HSCT to the University Hospital of Basel during 2004 and 2005, 120 patients had a complete database and were included in this retrospective study. The study was approved by the local Ethics Committee.
For every patient, information about age, sex, diagnosis leading to HSCT, type of HSCT (allogeneic, autologous or syngeneic), length of hospital stay, death during hospital stay, treatment duration, dosage of immunosuppressive agents and development of GVHD (including results from biopsy specimens) were recorded.
Patients starting treatment with voriconazole, amphotericin B or caspofungin during hospital stay were identified and evaluated with regard to pDDIs and ADEs. Information regarding indication for antimycotic treatment, reasons for a change to another antimycotic agent and/or for therapy cessation were also retrieved from their medical records.
Treatment with antimycotic drugs
Conventional amphotericin B was uptitrated to a dose of 1 mg/kg per day. Patients who did not tolerate this dose were switched to lipid-based amphotericin B (uptitration to 5 mg/kg per day), to i.v. or oral voriconazole or to caspofungin. Voriconazole was usually first administered i.v. (first day 6 mg/kg q12 h, then 4 mg/kg q12 h) and, after some days, switched to the oral formulation in patients who were able to swallow (200 mg q12 h). Caspofungin was administered i.v. (first day 70 mg, then 50 mg per day).
As voriconazole is almost completely bioavailable, the exposure during oral administration was assumed to be similar to that during i.v. administration. Adverse events associated with voriconazole are, therefore, provided as pooled data (for i.v. and oral administration). In contrast, conventional amphotericin B and lipid-based amphotericin B were evaluated separately.
Evaluation of pDDIs
Potential DDIs among voriconazole, amphotericin B, caspofungin and comedicated drugs were assessed using the online drug-interaction program Drug-Reax from Thomson Healthcare, Greenwood Village, CO, USA. 20 Potential DDIs are DDIs identified by the drug-interaction program that may (but not necessarily have to) result in an adverse drug reaction. Potential DDIs were recorded only if a drug combination was administered longer than 1 day. Only pDDIs of major severity according to the drug-interaction program were considered for evaluation, except for the interaction between CYA and amphotericin B, which is categorized as a pDDI of moderate severity by Drug-Reax.
Evaluation of ADEs
Patients were screened solely for renal and hepatic ADEs and for electrolyte disturbances during treatment with voriconazole, amphotericin B and/or caspofungin ( Table 1) . As a consequence of the retrospective study design, it could not be verified whether patients were systematically screened for ADEs pertaining to other organ classes. In addition, patients were screened for ADEs that may have resulted from the pDDIs detected.
An ADE was defined as any adverse event occurring during treatment with one of the antimycotic agents investigated with or without coadministration of interact- Table 1 Reference values and thresholds for adverse drug events concerning renal function, electrolytes, liver enzymes and bilirubin ing drugs and irrespective of a causal relationship. Baseline values were defined as the mean of five values before the antimycotic treatment or the interacting drug combination was started.
Drug-induced renal impairment was assessed on the basis of a change in the glomerular filtration rate, estimated by calculation of creatinine clearance (CrCl) according to the following formula: 21 Creatinine clearance ðml=minÞ ¼ 150 À age ðyearsÞÂweight ðkgÞ serum creatinine ðmmol=lÞ À10% for females, þ 10% for males A renal ADE was defined as a drop in the CrCl value by greater than or equal to one-third compared with baseline values. Electrolyte disturbances were defined as ADEs when X3 consecutive values were out of the normal range in patients with normal baseline values or when X3 consecutive values showed a X10% increase or decrease in patients with baseline values that were out of the normal range. The total serum calcium concentrations were corrected for the serum albumin concentration. 22 As surrogate parameters indicating hepatic ADEs, the changes in alanine aminotransferase, alkaline phosphatase and/or bilirubin were evaluated. Changes in the activities of liver enzymes were classified as ADEs depending on baseline values, as explained in Table 1 . For serum bilirubin, the presence of X3 consecutive values X50 mmol/l was classified as an ADE. None of the patients investigated had a serum bilirubin baseline value X50 mmol/l.
Specific events possibly resulting from pDDIs, for example, CYA blood concentrations above the therapeutic range because of coadministration with voriconazole, were evaluated separately. The therapeutic range for CYA determined in whole blood was defined as 100-400 mg/l using the CEDIA (cloned enzyme donor immunoassay) method. This therapeutic range was not adjusted specifically for HSCT recipients and/or for time after transplantation, as no reliable reference range exists for this group of patients. 23, 24 Causality assessment Causality for each ADE, caused directly by a drug or indirectly through a pDDI, was assessed according to the WHO Uppsala Monitoring Centre causality assessment system. 25 An ADE was classified as unlikely if the temporal relationship was not clear and if there were other more likely reasons explaining the ADE observed. The ADE was rated as possible if there was a reasonable temporal relationship, but other reasons (drugs, disease) were detectable that may have contributed to the event observed. In case of a probable causality assessment, there was a clear temporal relationship and no other causes contributing to the event were evident. For an ADE of definite causality, a positive rechallenge and/or another plausible explanation showing causality (for example, positive response to a specific antidote) was required. A positive dechallenge was not a major criterion for causality assessment, because damage to kidney or liver can be long lasting.
Statistical analysis
For categorical variables, the w 2 -test or, if appropriate, Fisher's exact test was used. Statistical analyses for normally distributed variables were performed using the independent two-sided Student's t-test and for not normally distributed numerical variables using the Mann-Whitney U-test. A P-value o0.05 was considered to be statistically significant. All analyses were performed using SPSS for Windows version 15.0 (SPSS Inc, Chicago, IL, USA).
Results
Patient characteristics
A total of 120 patients (61% males) admitted for HSCT were included in this retrospective study. The median age was 47.5 years (range 18-72 years). The most common reasons for HSCT were AML in 35%, multiple myeloma in 24% and Hodgkin's disease in 7% of patients studied. Allogeneic HSCT was performed in 58%, autologous HSCT in 40% and syngeneic HSCT in 2% of patients. GVHD was confirmed by biopsies in 21 patients (18%) and suspected in another 11 patients (9%). It occurred only in patients after allogeneic transplantation. Six patients (5%) died during hospital stay.
Treatment with voriconazole, amphotericin B and caspofungin
Of the 120 patients studied, 36 (30%) received treatment with at least one of the antimycotic drugs of interest, mainly because of suspected or proven aspergillosis or, in high-risk patients, for prophylactic reasons. A total of 67 antimycotic drugs were newly prescribed to these 36 patients during their hospital stay (voriconazole (n ¼ 28), conventional amphotericin B (n ¼ 14), lipid-based amphotericin B (n ¼ 15) and caspofungin (n ¼ 10)). Every patient was only treated once with the same antimycotic drug during hospitalization, except for three patients receiving voriconazole during two different periods of time. In 14 of the 36 patients (39%), a change from one to another antimycotic drug was made: in six patients because of worsening renal function during treatment with conventional amphotericin B and in three, because of fever of unknown origin. Common reasons for stopping the antimycotic drug prescribed were a change to another antimycotic drug or lack of confirmation of suspected aspergillosis.
In comparison with patients without antimycotics, patients receiving antimycotic drugs had AML (61 vs 24%; Po0.001) and underwent allogeneic HSCT (86 vs 45%; Po0.001) more often. Consequently, they suffered more frequently from GVHD (58 vs 13%; Po0.001), were treated with a higher cumulative dose of glucocorticoids (median (range) of prednisolone equivalents 2020 (25-11580) vs 52 (23-7010) mg; Po0.001) and were more often prescribed CYA (83 vs 43%; Po0.001). Although the mean daily dose of CYA adjusted to body weight was lower for patients treated with antimycotics (3.1 vs 4.2 mg/kg/d; P ¼ 0.003), no difference was observed in the median CYA concentration between the two groups (180 vs 185 mg/l; P ¼ 0.580). The median length of hospital stay was almost twice as long compared with patients not requiring antimycotic treatment (40.5 vs 24 days; Po0.001). Five patients (14%) in the group with antimycotic treatment died during hospital stay, significantly more than those in the comparison group (1%; P ¼ 0.009).
ADEs during antimycotic treatment
Considering ADEs related to antimycotic drug use, 122 events were detected in 32 of 36 patients (89%). In total, 54 (44% of the ADEs) ADEs were probably or possibly related to an antimycotic drug and 9 (7%) ADEs were probably related (Table 2 and Figure 1) . No ADE associated with one of the antimycotic drugs used was judged to have a definite causality. Conventional amphotericin B was considered as probably related with decreased CrCl in three cases (baseline CrCl was normal in all three patients) and with hypokalemia or hyperkalemia secondary to acute renal failure in one case each. Amphotericin B-induced decrease in CrCl returned to baseline in one of the three patients affected, whereas renal function recovered only partially in the other two patients. Lipid-based amphotericin B was considered to be the probable cause of hypomagnesemia in one case and voriconazole of hypokalemia in three patients ( Table 2 ). The low potassium and magnesium levels associated with these drugs returned to normal after an increase in supplementation. In one case, hypokalemia was probably associated with an accidental overdose of voriconazole (1200 mg for 1 day), but normalized within 3 days after potassium supplementation.
Although voriconazole and caspofungin were associated with a total of 2.1 and 1.8 ADEs per prescription, respectively, a frequency that was higher than the 1.6 ADEs per prescription for conventional or lipid-based amphotericin B, the proportion of ADEs with possible and/ or probable causality was higher for conventional and lipid-based amphotericin B (Table 2 and Figure 1 ).
DDIs with antimycotic drugs
Of the 36 patients treated with antimycotics, 31 (86%) had a total of 57 pDDIs associated with antimycotic drugs (Table 3) . The proportion of patients with pDDIs ranged from 64% for those treated with conventional amphotericin B to 84% for those receiving voriconazole. CYA was the comedicated drug that was most commonly implicated in pDDIs with the antimycotic drugs evaluated (involved in 48 of the 57 pDDIs).
Of the 31 patients with pDDIs, 26 (84%) experienced one or more ADEs of any causality. A total of 19 of the 57 pDDIs (33%) resulted probably or possibly in an ADE, and 5 of them (9%) were a probable cause of an ADE. A total of 19 of the 63 probable or possible ADEs (30%) and 5 of the 9 probable ADEs (56%) were judged to be caused by a DDI. Of the five ADEs with probable causality resulting from DDIs (observed in four patients), four originated from an interaction between voriconazole and CYA. These patients had increased CYA blood concentrations and a decrease in CrCl. The fifth ADE of probable causality was a decrease in CrCl due to the additive nephrotoxic effects of CYA and conventional amphotericin B. Renal function recovered in all patients after withdrawal of one of the interacting drugs and returned to baseline CrCl within a margin of ± 12%. Similarly, the CYA blood concentration normalized after dose reduction in all cases.
Discussion
About 90% of patients with antimycotic treatment experienced electrolyte disturbances and/or abnormalities of renal or hepatic function (a total of 122 ADEs). In 44% of them, the observed ADEs were probably or possibly related to treatment with an antimycotic drug and 30% of these ADEs were judged to be caused by a DDI. A total of 8% of all ADEs were probably related to antimycotics and 56% of them were due to a DDI. Although the rate of ADEs per prescription was slightly higher for voriconazole and caspofungin than for conventional or lipid-based amphotericin B, the proportion of probable ADEs was 22% for conventional amphotericin B, between 4 and 6% for lipid-based amphotericin B and voriconazole and 0% Table 2 Adverse drug events in patients with antimycotic treatment (n ¼ 36) for caspofungin. These findings suggest that lipid-based amphotericin B, voriconazole and caspofungin are safer than conventional amphotericin B. This is supported by various efficacy trials in HSCT recipients and in other patient populations treated for invasive aspergillosis, febrile neutropenia, Candida or other invasive fungal infections. 2, [26] [27] [28] [29] [30] [31] [32] In our study, the proportion of patients with pDDIs ranged from 64 to 84%, depending on the antimycotic drug used. By screening the entire medication list for pDDIs and by including not only pDDIs of major severity, an even higher prevalence might have been reached. In patients in medical wards, prevalence estimates for pDDIs assessed for all drugs prescribed were up to 68%. [33] [34] [35] Of the 57 pDDIs found in our study, 7 and 26% resulted in ADEs with a probable and possible causality, respectively. In a retrospective study including patients from an intensive care and an infectious disease unit, a total of 116 pDDIs were recorded in 150 antimycotic treatment episodes with amphotericin B, fluconazole, itraconazole and flucytosine. 36 About 19% of pDDIs, all involving amphotericin B, had clinical consequences such as hypokalemia, nephrotoxicity and/or an increase in serum creatinine. Half of the recorded pDDIs between amphotericin B and CYA resulted in decreased renal function, 36 a similar rate as observed in our study when considering ADEs with probable causality. Another retrospective cohort study assessed the frequency of pDDIs associated with fluconazole, itraconazole or ketoconazole in hospitalized patients treated for systemic fungal infections. 37 The prevalence of pDDIs was 70% in patients administered azoles; but in only 0.5% of the patients with a pDDI, was the interacting drug combination considered to have contributed to the manifestation of an ADE. 37 On the basis of our findings and comparable Figure 1 Occurrence of adverse drug events (ADEs) by causality for each of the antimycotic drugs investigated. 15, 38 The susceptibility for ADEs is dependent on the plasma concentration of each agent, the drug formulation and inter-patient variability. 39 An empiric dose reduction of 50% for CYA and 66% for tacrolimus has been proposed, along with close monitoring for a week after beginning and finishing treatment with voriconazole. 15, 39, 40 The combination of voriconazole and sirolimus is contraindicated according to product information, 41 but sirolimus doses reduced by 70-90% have been used safely in combination with voriconazole. [42] [43] [44] In our study, no ADE was observed in a patient administered sirolimus (3 mg) as the initial dose, followed by 1 mg every 3 days in combination with voriconazole. Although we found no significant difference comparing the CYA blood concentrations in patients using antimycotics with those who do not, the mean CYA doses were significantly lower (3.1 vs 4.2 mg/kg/d; P ¼ 0.003), reflecting awareness of the potential risk for DDIs. Nevertheless, four out of the five ADEs probably resulting from a DDI were due to the combination of voriconazole and CYA. Dose adjustment and consequent monitoring of CYA concentrations, as well as clinical monitoring of patients treated with this combination, are therefore mandatory.
According to product information and our drug interaction program, the combination of CYA with caspofungin was rated as major. In our study, only one patient showed an elevation in alanine aminotransferase, which was possibly related to the interacting drug combination. Other retrospective studies in liver transplant patients, HSCT recipients and in patients after solid organ transplantation also did not reveal a major hepatic risk associated with concomitant administration of caspofungin and CYA. 17, 19, [45] [46] [47] However, a retrospective evaluation of hepatic drug safety is limited, as hepatic dysfunction after allogeneic HSCT is common, occurring in 84% of patients, and may be because of a variety of causes such as GVHD, infections such as viral hepatitis, hepatic venoocclusive disease and/or recurrence of underlying disease. 48 Owing to the retrospective study design, ADEs affecting organs other than the liver or kidney were not assessed, as a systematic evaluation of patients could not be guaranteed. Transient visual disorders were frequently reported during voriconazole treatment in other studies, 27 ,28 but were not detected in our study. Therefore, the number of ADEs, especially related to voriconazole, may have been underestimated. In addition, causality assessment of ADEs was complicated by the complexity of the clinical situation of HSCT patients. In particular, the evaluation of druginduced electrolyte disturbances may be of limited importance, as regular monitoring and adjustment of substitution with potassium and magnesium during hospitalization may have prevented clinical consequences. Finally, the small number of patients included did not permit the detection of statistical differences between the antimycotic drugs evaluated with regard to ADEs, pDDIs or risk factors.
In conclusion, although most HSCT patients treated with antimycotics have pDDIs, they only rarely have ADEs with a probable relation to drug treatment and/or DDIs. Monitoring the blood and serum levels of the drugs implicated and clinical monitoring of patients are mandatory to keep the frequency of ADEs within an acceptable range in this high-risk population.
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